0001104659-18-038619.txt : 20180606 0001104659-18-038619.hdr.sgml : 20180606 20180606170028 ACCESSION NUMBER: 0001104659-18-038619 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180604 FILED AS OF DATE: 20180606 DATE AS OF CHANGE: 20180606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KOVEN ANDREW I CENTRAL INDEX KEY: 0001258673 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37691 FILM NUMBER: 18884406 MAIL ADDRESS: STREET 1: 3 COLUMBUS CIRCLE, SUITE 1710 STREET 2: C/O ARALEZ PHARMACEUTICALS INC. CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aralez Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001660719 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7100 WEST CREDIT AVENUE, SUITE 101 CITY: MISSISSAUGA STATE: A6 ZIP: L5N 0E4 BUSINESS PHONE: 905-876-1118 MAIL ADDRESS: STREET 1: 7100 WEST CREDIT AVENUE, SUITE 101 CITY: MISSISSAUGA STATE: A6 ZIP: L5N 0E4 4 1 a4.xml 4 X0306 4 2018-06-04 0 0001660719 Aralez Pharmaceuticals Inc. ARLZ 0001258673 KOVEN ANDREW I C/O ARALEZ PHARMACEUTICALS INC., 7100 WEST CREDIT AVENUE, SUITE 101 MISSISSAUGA A6 L5N 0E4 ONTARIO, CANADA 0 1 0 0 President & Chief Business Off Common Shares, without par value 2018-06-04 4 S 0 156573 0.3742 D 1183419 D This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 369,168 restricted stock units, which were previously granted on June 3, 2015 and which vested on June 3, 2018. This transaction was executed in multiple trades at prices ranging from $0.3700 to $0.3803. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. /s/ Christopher R. Freeland, attorney-in-fact for Andrew I. Koven 2018-06-06